Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy.
<h4>Purpose</h4>The 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guideline on HER2 testing in breast cancer permits reclassification of cases with HER2-equivocal results by FISH. The impact of such reclassification is unclear. We sought to determine the prop...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Public Library of Science (PLoS)
2020-01-01
|
| Colección: | PLoS ONE |
| Acceso en línea: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0241775&type=printable |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|